GlassScriptPhysician profile
Puneet Sud
NPI 1598762346
$4,993.61
in general payments reported to CMS, 2019-2025
32 companies · $859 in 2025
The $859 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $476 · 2020: $258 · 2021: $569 · 2022: $691 · 2023: $1,284 · 2024: $857 · 2025: $859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,999.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,153.12 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $658.94 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $653.72 | 2019-2025 | |
| Abbvie INC. | $528.74 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $213.33 | 2021-2025 | Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $170.57 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $169.79 | 2019-2023 | |
| Abbott Laboratories | $164.72 | 2021-2025 | Freestyle Libre 3 |
| Mylan Specialty L.P. | $130.34 | 2022-2024 | Yupelri |
| Orexo US, INC. | $128.01 | 2020-2024 | Zubsolv |
| Nestle Healthcare Nutrition INC. | $120.75 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $111.05 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $91.40 | 2022-2025 | Zoryve, Seglentis |
| Exact Sciences Corporation | $81.82 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $70.85 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $62.17 | 2024-2025 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $54.53 | 2019-2023 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $53.01 | 2021-2022 | |
| Gilead Sciences, INC. | $43.84 | 2020-2023 | |
| Phathom Pharmaceuticals, INC. | $42.26 | 2023-2024 | Voquezna |
| Amgen INC. | $41.76 | 2022-2023 | Otezla, Repatha |
| Dexcom, INC. | $35.38 | 2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.48 | 2021 | |
| Supernus Pharmaceuticals, INC. | $29.52 | 2023 | Qelbree |
| Astellas Pharma US INC | $26.98 | 2019 | |
| Corcept Therapeutics | $21.12 | 2024 | Korlym |
| Shire North American Group INC | $20.01 | 2019 | |
| Braeburn INC. | $19.43 | 2025 | Brixadi |
| Evoke Pharma, INC. | $18.02 | 2025 | |
| Currax Pharmaceuticals LLC | $17.95 | 2025 | Contrave |
| Mdd US Operations, LLC | $13.80 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Puneet Sud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.